Published Date: 02 Mar 2023
You may not have heard of respiratory syncytial virus (RSV). However, it killed more than 100,000 people worldwide in 2019, making it the leading cause of death among children under the age of one.
Read Full News1.
CD39 Blockade Shows Potential in Early-Stage Lung Cancer
2.
Q&A: Researchers discuss identifying potential new protein targets for melanoma therapeutics
3.
PFS in Multiple Myeloma Is Improved by Daratumumab Added to Standard Therapy.
4.
Venetoclax Combo Shows Promise in Younger Patients With AML
5.
Long Wait Times on the Other Side of the Pond: King Charles' Cancer Diagnosis.
1.
Understanding SVR Normal Range: A Guide to Achieving Optimal Health
2.
Engineering the Future of Oncology with CAR- Natural Killer Cell Design & Therapeutics
3.
Hope in Numbers: Understanding AML Leukemia Survival Rates and Emerging Therapies
4.
Boosting Checkpoint Immunotherapy in Hodgkin Lymphoma with JAK Inhibition: Advances & Insights
5.
CAR-T Cell Therapy for B-Cell Acute Lymphoblastic Leukemia: A Comprehensive Review
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Newer Immunotherapies for Myeloma- A Comprehensive Overview
2.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion III
3.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part V
4.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part II
5.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation